/
PBYI
$8.19+$0.08 (+0.99%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$412.8M
51M shares
52-week range
$3.03 – $8.41
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $251.0M | $272.3M | $225.1M | $253.2M | $228.0M | $235.6M | $230.5M | $228.4M |
| Cost of revenue | $34.6M | $36.8M | $39.4M | $63.7M | $55.1M | $62.7M | $64.4M | $58.2M |
| Gross profit | $216.4M | $235.4M | $185.7M | $189.5M | $172.9M | $173.0M | $166.1M | $170.2M |
| Gross margin | 86.2% | 86.5% | 82.5% | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% |
| R&D | $164.9M | $132.9M | $97.7M | $71.9M | $52.2M | $50.4M | $54.9M | $62.1M |
| Operating income | −$94.7M | −$75.6M | −$30.4M | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M |
| EBITDA | −$95.2M | −$52.4M | −$35.7M | −$4.7M | $21.9M | $47.5M | $48.1M | $53.3M |
| Net income | −$113.6M | −$75.6M | −$60.0M | −$29.1M | $2.0K | $21.6M | $30.3M | $31.1M |
| Net margin | -45.3% | -27.8% | -26.7% | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| EPS (diluted) | -2.99 | -2.13 | -1.52 | -0.72 | 0.02 | 0.45 | 0.62 | 0.61 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $222M | $0.29 | $0.27–$0.31 | 1 |
| 2027 | $219M | $0.20 | $0.17–$0.23 | 1 |
| 2028 | $216M | $0.12 | $0.12–$0.12 | 1 |
| 2029 | $213M | $0.04 | $0.04–$0.04 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$17.40
Price
$8.19
Implied upside
+112%
Peer comparison
PUMA BIOTECHNOLOGY INC
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
www.pumabiotechnology.com- Employees
- 179
- IPO / List date
- Mar 21, 2012
- HQ
- LOS ANGELES, CA
Held by traders on TradeandTell
No one on the platform currently holds PBYI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,942,413 | $12.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PBYI yet.
